RECRUITING

Use of Indocyanine Green in Pancreas Surgery

Description

This study evaluates the use of indocyanine green to predict postoperative pancreatic leaks in patients undergoing transection of the pancreas.

Study Overview

Study Details

Study overview

This study evaluates the use of indocyanine green to predict postoperative pancreatic leaks in patients undergoing transection of the pancreas.

Assessing the Role of Intraoperative Indocyanine Green Perfusion of the Transected Pancreas in Predicting Postoperative Pancreatic Leaks

Use of Indocyanine Green in Pancreas Surgery

Condition
Pancreatic Carcinoma
Intervention / Treatment

-

Contacts and Locations

Portland

OHSU Knight Cancer Institute, Portland, Oregon, United States, 97239

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant scheduled for open pancreaticoduodenectomy or distal pancreatectomy for any diagnosis
  • * Participant ≥ 18 years of age
  • * Ability to understand nature and individual consequences of clinical trial
  • * Written informed consent from participant or legally authorized representative
  • * For participants of childbearing potential, a negative pregnancy test and adequate contraception until 14 days after trial intervention
  • * Participant needs to have an operative drain (any closed suction drain) after the procedure
  • * Participants that do not require arterial reconstruction
  • * Participants that require minor portal venous recounstructions including patch venoplasty
  • * Patients with previous history of adverse reaction to contrast dye, ICG or components of the dye
  • * Prior pancreatectomy
  • * Known diagnosis of hepatic insufficiency, hepatitis, liver fibrosis or cirrhosis, or chronic pancreatitis
  • * Because this study focuses on hypoperfusion, patients will be excluded if in postoperative day 3-5 had any of the following: persistent SBP \<90 mmHg unresponsive to 1L crystalloid, unexpected ICU transfer, blood transfusion of \>2 units intraoperatively or 1 postoperatively, vasopressor treatment or ACLS protocol initiation
  • * Organ failure, anuria or NSQIP-identified complication will be reviewed by PI and attending surgeon and excluded
  • * Patients that require arterial reconstruction as part of their procedures

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

OHSU Knight Cancer Institute,

Patrick J Worth, PRINCIPAL_INVESTIGATOR, OHSU Knight Cancer Institute

Study Record Dates

2026-02